Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine versus midazolam crossover study in enduring anorexia nervosa
ACTRN12618001393246Phase 2Not yet recruiting
- Sponsor
- University of Otago
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine and midazolam in anorexia nervosa (AN), major depressive disorder (MDD), anxiety disorder and 1 more (2 arms), sponsored by University of Otago. Primary endpoints: Montgomery Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (HamA) and 1 more. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
ketaminemidazolam
03
Conditions
anorexia nervosa (AN)major depressive disorder (MDD)anxiety disorderobsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on ACTRN12618001393246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001393246.